The mesolimbic dopaminergic pathway represents one of the four major dopaminergic projection systems in the mammalian brain, originating in the ventral tegmental area (VTA) and projecting to limbic structures including the nucleus accumbens, amygdala, hippocampus, and prefrontal cortex 1. This pathway is fundamentally associated with reward processing, motivation, emotional regulation, and cognitive functions that are profoundly affected in Parkinson's disease 2. [1]
While Parkinson's disease is classically defined by nigrostriatal degeneration and motor symptoms, mesolimbic pathway involvement underlies the non-motor symptoms that significantly impact quality of life, including depression, anxiety, apathy, and cognitive impairment. Understanding mesolimbic dysfunction in PD provides critical insights into disease progression and therapeutic approaches 3. [2]
The ventral tegmental area is located in the midbrain, medial to the substantia nigra: [3]
Location and structure: [4]
Subregions: [5]
Cell types: [6]
The mesolimbic pathway projects to several limbic structures: [7]
Nucleus accumbens (NAc): [8]
Amygdala: [9]
Hippocampus: [10]
Prefrontal cortex (PFC): [11]
VTA dopamine neurons exhibit distinctive firing patterns: [12]
Tonic firing: [13]
Burst firing: [14]
Firing heterogeneity: [15]
Mesolimbic dopamine signaling operates through multiple mechanisms: [16]
Phasic release: [17]
Tonic extracellular dopamine: [18]
Compartment-specific release: [19]
The mesolimbic pathway is central to reward processing: [20]
Reward prediction error: [21]
Reward valuation: [22]
Learning: [23]
Mesolimbic dopamine modulates motivational states: [24]
Wanting: [25]
Liking (hedonia): [26]
Learning: [27]
The mesolimbic pathway influences emotional functions: [28]
Mood regulation: [29]
Anxiety: [30]
Stress response: [31]
Parkinson's disease affects mesolimbic structures: [32]
VTA neuron loss: [33]
Dopamine depletion: [34]
Lewy body pathology: [35]
Mesolimbic dysfunction underlies PD non-motor symptoms: [36]
Depression: [37]
Anxiety: [38]
Apathy: [39]
Cognitive impairment: [40]
Dopamine agonist therapy can induce ICDs: [41]
Common ICDs: [42]
Mechanism: [43]
Risk factors: [44]
Common PD medications have mesolimbic effects: [45]
Pramipexole: [46]
Ropinirole: [47]
Rotigotine: [48]
Treating depression in PD requires careful consideration: [49]
SSRIs: [50]
Tricyclic antidepressants: [51]
Dopamine agonists: [52]
DBS affects mesolimbic circuits: [53]
STN DBS: [54]
VTA/Nacc DBS:
Neuroimaging reveals mesolimbic changes:
DaTscan:
FDG-PET:
Dopamine receptor imaging:
Structural changes in mesolimbic regions:
Volumetric MRI:
Diffusion MRI:
Modeling mesolimbic dysfunction:
6-OHDA lesions:
MPTP:
α-Synuclein models show mesolimbic pathology:
Viral vector models:
Transgenic models:
Complex circuits mediate mesolimbic functions:
VTA-NAc loop:
VTA-amygdala circuit:
VTA-PFC circuit:
Mesolimbic and nigrostriatal pathways interact:
Anatomical interactions:
Functional interactions:
Identifying at-risk patients:
Clinical predictors:
Neuroimaging predictors:
Genetic factors:
Tailoring treatment to individual patients:
Motor symptoms:
Non-motor symptoms:
Future treatment strategies:
D3-selective agonists:
VTA-targeted therapies:
The mesolimbic dopaminergic pathway plays essential roles in reward processing, motivation, and emotional regulation that are profoundly disrupted in Parkinson's disease. While nigrostriatal degeneration defines the motor symptoms of PD, mesolimbic dysfunction underlies the non-motor symptoms that significantly impact patient quality of life. Understanding the complex interactions between motor and limbic circuits, developing biomarkers for early identification of mesolimbic dysfunction, and optimizing treatment strategies that address both motor and psychiatric symptoms represent critical priorities for improving care in Parkinson's disease.
Grace AA, Bunney BS. The control of firing pattern in ventral tegmental area dopamine neurons. J Neurosci. 1984;4(11):2877-2890. 1984. ↩︎
Overton PG, Clark D. Burst firing in midbrain dopaminergic neurons. Brain Res Rev. 1997;25(3):312-334. 1997. ↩︎
Schultz W. Getting formal with dopamine and reward. Neuron. 2002;36(2):241-263. 2002. ↩︎
Zhang CL, Katoh M, Sulzer D. Striatal dopamine release. J Neurosci. 2009;29(47):14764-14774. 2009. ↩︎
Grace AA. Tonic vs. phasic dopamine release. Eur J Neurosci. 2016;44(10):2818-2831. 2016. ↩︎
Descarries L, Bérubé-Carrière N, Riad M, Salesse SD, Mendez JA, Trudeau LE. Dopamine in the CNS. Handb Exp Pharmacol. 2008;(175):91-118. 2008. ↩︎
Schultz W. Predictive reward signal of dopamine neurons. J Neurophysiol. 1998;80(1):1-27. 1998. ↩︎
Knutson B, Adams CM, Conover JM, et al. Anticipation of monetary reward selectively activates nucleus accumbens. Neuroreport. 2001;12(16):3683-3687. 2001. ↩︎
Berridge KC. The debate over dopamine's role in reward. Psychopharmacology (Berl). 2007;191(3):391-431. 2007. ↩︎
Flagel SB, Clark JJ, Robinson TE, et al. A selective role for dopamine in stimulus-reward learning. Nature. 2011;469(7328):53-57. 2011. ↩︎
Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience? Brain Res Brain Res Rev. 1998;28(3):309-369. 1998. ↩︎
Yin HH, Knowlton BJ, Balleine BW. Blockade of NMDA receptors in the dorsomedial striatum prevents action-outcome learning. Eur J Neurosci. 2006;23(11):2903-2908. 2006. ↩︎
LamYW, Man HY. Dopamine and mood disorders. In: Neurobiology of Mood Disorders. 2011. 2011. ↩︎
Weintraub D, et al. Impulse control disorders in Parkinson's disease. Arch Neurol. 2010;67(5):589-595. 2010. ↩︎
Nestler EJ, Hyman SE. Animal models of mood disorders. Nat Neurosci. 2010;13(10):1161-1169. 2010. ↩︎
Jellinger KA. Neuropathology of Parkinson's disease. J Neural Transm Suppl. 2001;62:47-64. 2001. ↩︎
Kalia LV, Lang AE. Parkinson's disease. Lancet. 2015;386(9996):896-912. 2015. ↩︎
Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24(2):197-211. 2003. ↩︎
Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF. A systematic review of prevalence studies of depression in Parkinson's disease. Mov Disord. 2008;23(2):183-189. 2008. ↩︎
Pontone GM, Williams JR, Anderson KE, et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord. 2009;24(9):1333-1338. 2009. ↩︎
Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol. 2008;15(Suppl 1):14-20. 2008. ↩︎
Owen AM. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist. 2004;10(6):525-537. 2004. ↩︎
Voon V, Fernandez HH, Rizos J, et al. Impulse control disorders in Parkinson's disease. Mov Disord. 2011;26(2):183-188. 2011. ↩︎
Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease. Arch Neurol. 2010;67(5):589-595. 2010. ↩︎
Antonini A, Cilia R. Behavioural adverse effects of dopaminergic treatments. J Neural Transm. 2009;116(10):1173-1182. 2009. ↩︎
Kase H, Jenner P. Pramipexole in the treatment of Parkinson's disease. Expert Opin Pharmacother. 2002;3(10):1405-1415. 2002. ↩︎
Kvernmo T, Hartter S, Burger E. A review of the receptor-binding and pharmacokinetic properties of ropinirole. CNS Drugs. 2006;20(5):389-397. 2006. ↩︎
Nutt JG, et al. Rotigotine transdermal system in Parkinson's disease. Mov Disord. 2008;23(13):1864-1872. 2008. ↩︎
Menza M, et al. SSRIs in the treatment of depression in Parkinson's disease. Mov Disord. 2009;24(12):1763-1772. 2009. ↩︎
Tesei S, Antonini A, Canesi M, Zecchinelli L, Mariani C, Pezzoli G. Tolerability of paroxetine in Parkinson's disease. J Neural Transm. 2000;107(3):331-334. 2000. ↩︎
Barone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in Parkinson's disease. Lancet Neurol. 2010;9(6):573-580. 2010. ↩︎
Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V. Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. Neurology. 2001;56(4):548-551. 2001. ↩︎
Sani SB, Eslinger PJ, Brown GD, et al. Deep brain stimulation for Parkinson's disease: validation studies. J Neurosurg. 2012;116(1):84-94. 2012. ↩︎
[Stoffers D, Booij J, Winogrodzka A, et al. [123I]FP-CIT SPECT in Parkinson's disease. 2007. ↩︎
Huang C, Mattis P, Tang C, et al. FDG-PET in early PD. J Neural Transm. 2007;114(3):337-342. 2007. ↩︎
Rinne JO, Laihinen A, Rinne UK, et al. PET study of dopamine receptors in PD. Mov Disord. 1993;8(3):304-308. 1993. ↩︎
Gennatas ED, et al. MRI volumetry in PD. Neurology. 2012;79(8):846-854. 2012. ↩︎
Zhang K, et al. Diffusion tensor imaging in PD. J Neurol Neurosurg Psychiatry. 2011;82(12):1282-1288. 2011. ↩︎
Ungerstedt U. 6-OHDA and Parkinson's disease. Eur Neurol. 1971;6(1):50-55. 1971. ↩︎
Langston JW, Irwin I, Ricaurte GA. Neurotoxicity of MPTP. Pharmacol Ther. 1987;32(1):19-49. 1987. ↩︎
Kirik D, et al. Alpha-synuclein and PD. J Neurosci. 2002;22(7):2780-2791. 2002. ↩︎
Masliah E, et al. Transgenic alpha-synuclein model. Science. 2000;287(5456):1265-1269. 2000. ↩︎
Ikemoto S. Brain reward circuitry beyond VTA-NAc. Brain Res Rev. 2007;56(1):3-28. 2007. ↩︎
Lee HJ, et al. Amygdala-VTA interactions. J Neurosci. 2008;28(6):1385-1404. 2008. ↩︎
Seamans JK, Yang CR. The principal features and mechanisms of dopamine modulation in the prefrontal cortex. Prog Neurobiol. 2004;74(1):1-58. 2004. ↩︎
Oades RD, Halliday GM. VTA and SNc interactions. Brain Res. 1987;434(2):117-165. 1987. ↩︎
Salamone JD, Correa M. The mysterious motivational functions of mesolimbic dopamine. Neuron. 2012;76(3):470-485. 2012. ↩︎
Leentjens AF. Depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci. 2009;21(1):1-7. 2009. ↩︎
Remy P, Doder M, Lees A, Turjanski N, Brooks D. Depression in Parkinson's disease. Brain. 2005;128(Pt 6):1314-1322. 2005. ↩︎
Klein J, et al. Genetic susceptibility to PD. Neurobiol Aging. 2007;28(3):417-426. 2007. ↩︎
Olanow CW, Stocchi F. Levodopa: a new look at an old friend. Mov Disord. 2008;23(11):1521-1532. 2008. ↩︎
Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease. Lancet Neurol. 2009;8(5):464-478. 2009. ↩︎
Sokoloff P, et al. D3 dopamine receptors. Curr Opin Pharmacol. 2006;6(1):53-60. 2006. ↩︎
Barker RA, Bjorklund A. Cell therapy for Parkinson's disease. Trends Neurosci. 2007;30(10):517-524. 2007. ↩︎